Impact of mast cells in systemic lupus erythematosus: can inflammation be inhibited?
Systemic lupus erythematosus (SLE), is a complex chronic inflammatory autoimmune disease, with rheumatological manifestations, which afflicts mainly women. SLE presents various heterogeneous clinical aspects and different pathogeneses and involves the production of anti- DNA autoantibodies which are deposited as immune complexes in various organs and tissues, provoking inflammation. These diseases cause multiple tissue and organ damage in arthritis, skin lesions, hematologic changes, renal and neurologic disorders, and others (Table I). In SLE, serum contains anti-nucleus antibodies and anti-DNA antibodies that can be important biomarkers for patients suffering from this disease.
['Caraffa|Al|Al|', 'Gallenga|C E|CE|', 'Kritas|S K|SK|', 'Ronconi|G|G|', 'Conti|P|P|']
D000974:Antibodies, Antinuclear D015415:Biomarkers D006801:Humans D007249:Inflammation D008180:Lupus Erythematosus, Systemic D008407:Mast Cells
mast cell systemic lupus erythematosus inflammation cytokines IL-37